Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02537548
Recruitment Status : Recruiting
First Posted : September 1, 2015
Last Update Posted : July 19, 2018
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Southern California

Brief Summary:
This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that removes lymph nodes in this area to treat testicular seminoma and may experience fewer long-term toxicities, such as a second cancer, cardiovascular disease, metabolic syndrome (pre-diabetes), or lung disease.

Condition or disease Intervention/treatment Phase
Lymphadenopathy Stage I Testicular Seminoma Stage II Testicular Seminoma Other: Laboratory Biomarker Analysis Procedure: Retroperitoneal Lymph Node Dissection Not Applicable

Detailed Description:


I. Assess the recurrence free survival (RFS) at 2 years after RPLND when RPLND is used as a first line treatment for patients with testicular seminoma and low volume (=< 2cm) retroperitoneal disease.


I. Estimate the percent of patients, after treatment with RPLND, who can avoid external beam radiotherapy (XRT) or systemic chemotherapy (CTX) for seminoma.

II. Assess the complications associated with primary RPLND for seminoma.


Patients undergo RPLND.

After completion of study treatment, patients are followed up at 1 month, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Actual Study Start Date : August 28, 2015
Estimated Primary Completion Date : August 28, 2019
Estimated Study Completion Date : August 28, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment (RPLND)
Patients undergo RPLND.
Other: Laboratory Biomarker Analysis
Correlative studies

Procedure: Retroperitoneal Lymph Node Dissection
Undergo RPLND
Other Name: RPLND

Primary Outcome Measures :
  1. RFS [ Time Frame: From RPLND to the time of recurrence or death, whichever comes first., assessed at 2 years after RPLND ]
    Associated 95% confidence intervals will be constructed. Actuarial RFS will be calculated by the Kaplan Meier method. The recurrence location (pelvic, retroperitoneal, distant) will be calculated as a percentage of total recurrences to describe the clinical pattern of disease after relapse.

Secondary Outcome Measures :
  1. Long-term RPLND complication rates [ Time Frame: Up to 5 years ]
    The rate of short and long term complications will be calculated.

  2. RFS [ Time Frame: From RPLND to the time of recurrence or death, whichever comes first., assessed at 5 years after RPLND ]
    Associated 95% confidence intervals will be constructed. Actuarial RFS will be calculated by the Kaplan Meier method.

  3. Short-term RPLND complication rates [ Time Frame: Up to 12 months ]
    The rate of short and long term complications will be calculated.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pure seminoma after orchiectomy presenting with isolated retropreritoneal lymphadenopathy OR stage I pure seminoma with isolated retroperitoneal relapse. Relapse should be within 3 years
  • Lymphadenopathy in the retroperitoneum: at least one lymph node 1-3 cm in greatest dimension, no lymph node > 3 cm in greatest dimension, no more than 2 lymph nodes 1-3 cm in greatest dimension

    • Axial imaging of lymphadenopathy within 6 weeks of the date of RPLND
    • Retroperitoneal lymphadenopathy must be within the RPLND template
  • If there is borderline lymphadenopathy, defined as the largest retroperitoneal lymph node measuring 0.90 - 0.99 cm in the greatest dimension, an abdominal computed tomography (CT) scan should be repeated (recommend interval of 6 - 8 weeks); the same lymph node must demonstrate growth to >= 1.0 cm in the greatest dimension
  • Biopsy is not required, though if biopsy of the retroperitoneal node(s) was obtained, pathology must be consistent with pure seminoma
  • Chest imaging (x-ray, CT or magnetic resonance imaging [MRI]) negative for metastasis no more than 6 weeks prior to the date of RPLND
  • Primary tumor excised by radical inguinal orchiectomy and pathology consistent with pure seminoma
  • Serum alpha fetoprotein (AFP) not more than 1.5 times upper limit of normal, beta-human chorionic gonadotropin (HCG), lactate dehydrogenase (LDH) (per the local laboratory assay) within 14 days of RPLND
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1
  • Ability to understand and the willingness to sign a written informed consent
  • Serum coagulation studies (INR/PTT) and platelet counts suitable for surgery per surgeon discretion.

Exclusion Criteria:

  • Second primary malignancy
  • History of receiving chemotherapy or radiotherapy
  • Patients receiving any other investigational agent (s)
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02537548

Contact: Ileana Aldana 323-865-0702

United States, California
Loma Linda University Medical Center Recruiting
Loma Linda, California, United States, 92350
Contact: Tami Terry    909-558-7117   
Contact: Candace Turner-Santacroce    909-558-7113   
Principal Investigator: Brian R Hu, MD         
USC / Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Aldana Ileana    323-865-0702   
Principal Investigator: Siamak Daneshmand, MD         
Sub-Investigator: Brian Hu, MD         
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Emil B Lavaki    415-514-0554   
Principal Investigator: Maxwell V Meng, MD         
Stanford University Hospitals & Clinics Recruiting
Stanford, California, United States, 94305
Contact: Ned Realiza    650-498-8496   
Contact: Fernando Serrano    650-724-3332   
Principal Investigator: Eila Skinner, MD         
United States, Georgia
Emory University Recruiting
Atlanta, Georgia, United States, 30322
Contact: Camden Spade    404-778-4823   
Contact: Jennifer Adouli    (404) 778-7397      
Principal Investigator: Mehrdad Alemozaffar, MD         
United States, Illinois
University of Chicago Medical Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Brittany Pulliam   
Principal Investigator: Scott Eggener, MD         
United States, Indiana
Indiana University Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Molly Cheviron    317-274-3148   
Principal Investigator: Clint Cary, MD         
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting
Baltimore, Maryland, United States, 21205
Contact: Ting Wang, MS    410-502-2299   
Principal Investigator: Phil Pierorazio, MD         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Jane Smith, RN    507-266-8788   
Principal Investigator: Steve Boorjian, MD         
United States, New Jersey
Rugters Cancer Institute of New Jersey Recruiting
New Brunswick, New Jersey, United States, 08903-2681
Contact: Christopher Karnicki    732-235-7771   
Principal Investigator: Thomas Jang, MD         
United States, Oklahoma
Stephenson Cancer Center, University of Oklahoma Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Ingrid Block, MS    405-271-8777   
Principal Investigator: Kelly Stratton, MD         
United States, Texas
UTSouthwestern Medical Center Recruiting
Dallas, Texas, United States, 75390-9110
Contact: Allison Beaver    214-645-8765   
Contact: Doreen Simonsen    214-645-8790   
Principal Investigator: Aditya Bagrodia, MD         
Sponsors and Collaborators
University of Southern California
National Cancer Institute (NCI)
Principal Investigator: Siamak Daneshmand University of Southern California

Responsible Party: University of Southern California Identifier: NCT02537548     History of Changes
Other Study ID Numbers: 4T-14-1
NCI-2015-01177 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
4T-14-1 ( Other Identifier: USC / Norris Comprehensive Cancer Center )
P30CA014089 ( U.S. NIH Grant/Contract )
First Posted: September 1, 2015    Key Record Dates
Last Update Posted: July 19, 2018
Last Verified: July 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Lymphatic Diseases